The Use of Dabigatran in Elderly Patients

  • Commentary S
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Recent approval by the {US} Food and Drug Administration ({FDA}) of dabigatran etexilate, an oral direct thrombin inhibitor, for the prevention of stroke in patients with atrial fibrillation will likely extend its administration in elderly patients. The risk of major overdosage of dabigatran etexilate in this population is, however, much increased owing to frequent renal function impairment, low body weight, drug interactions that cannot be detected with a routine coagulation test, and no antagonist available. We report herein 2 clinical cases, including 1 fatal case, illustrating our concern regarding the risk of bleeding events in elderly patients.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • See Invited Commentary

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free